TY - JOUR
T1 - Does the Fetus Limit Antibiotic Treatment in Pregnant Patients with COVID-19?
AU - Ramírez-Lozada, Tito
AU - Loranca-García, María Concepción
AU - Fuentes-Venado, Claudia Erika
AU - Rodríguez-Cerdeira, Carmen
AU - Ocharan-Hernández, Esther
AU - Soriano-Ursúa, Marvin A.
AU - Farfán-García, Eunice D.
AU - Chávez-Gutiérrez, Edwin
AU - Ramírez-Magaña, Xóchitl
AU - Robledo-Cayetano, Maura
AU - Loza-Mejía, Marco A.
AU - Santa-Olalla, Ivonne Areli Garcia
AU - Torres-Paez, Oscar Uriel
AU - Pinto-Almazán, Rodolfo
AU - Martínez-Herrera, Erick
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - During pregnancy, there is a state of immune tolerance that predisposes them to viral infec-tion, causing maternal-fetal vulnerability to the adverse effects of COVID-19. Bacterial coinfections significantly increase the mortality rate for COVID-19. However, it is known that all drugs, including antibiotics, will enter the fetal circulation in a variable degree despite the role of the placenta as a protective barrier and can cause teratogenesis or other malformations depending on the timing of exposure to the drug. Also, it is important to consider the impact of the indiscriminate use of antibiotics during pregnancy can alter both the maternal and fetal-neonatal microbiota, generating future repercussions in both. In the present study, the literature for treating bacterial coinfections in pregnant women with COVID-19 is reviewed. In turn, we present the findings in 50 pregnant women hospitalized diagnosed with SARS-CoV-2 without previous treatment with antibiotics; moreover, a bacteriological culture of sample types was performed. Seven pregnant women had coinfection with Staphylococcus haemolyticus, Staphylococcus epidermidis, Streptococcus agalactiae, Escherichia coli ESBL +, biotype 1 and 2, Acinetobacter jahnsonii, Enterococcus faecium, and Clostridium difficile. When performing the antibiogram, resistance to multiple drugs was found, such as macrolides, aminoglycosides, sulfa, dihydrofolate reductase inhibitors, beta-lactams, etc. The purpose of this study was to generate more scientific evidence on the better use of antibiotics in these patients. Because of this, it is important to perform an antibiogram to prevent abuse of empirical antibiotic treatment with antibiotics in pregnant women diagnosed with SARS-CoV-2.
AB - During pregnancy, there is a state of immune tolerance that predisposes them to viral infec-tion, causing maternal-fetal vulnerability to the adverse effects of COVID-19. Bacterial coinfections significantly increase the mortality rate for COVID-19. However, it is known that all drugs, including antibiotics, will enter the fetal circulation in a variable degree despite the role of the placenta as a protective barrier and can cause teratogenesis or other malformations depending on the timing of exposure to the drug. Also, it is important to consider the impact of the indiscriminate use of antibiotics during pregnancy can alter both the maternal and fetal-neonatal microbiota, generating future repercussions in both. In the present study, the literature for treating bacterial coinfections in pregnant women with COVID-19 is reviewed. In turn, we present the findings in 50 pregnant women hospitalized diagnosed with SARS-CoV-2 without previous treatment with antibiotics; moreover, a bacteriological culture of sample types was performed. Seven pregnant women had coinfection with Staphylococcus haemolyticus, Staphylococcus epidermidis, Streptococcus agalactiae, Escherichia coli ESBL +, biotype 1 and 2, Acinetobacter jahnsonii, Enterococcus faecium, and Clostridium difficile. When performing the antibiogram, resistance to multiple drugs was found, such as macrolides, aminoglycosides, sulfa, dihydrofolate reductase inhibitors, beta-lactams, etc. The purpose of this study was to generate more scientific evidence on the better use of antibiotics in these patients. Because of this, it is important to perform an antibiogram to prevent abuse of empirical antibiotic treatment with antibiotics in pregnant women diagnosed with SARS-CoV-2.
KW - Antibiotics
KW - COVID-19
KW - Fetus
KW - Microbiota
KW - Placenta
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85125066184&partnerID=8YFLogxK
U2 - 10.3390/antibiotics11020252
DO - 10.3390/antibiotics11020252
M3 - Artículo
C2 - 35203854
AN - SCOPUS:85125066184
SN - 2079-6382
VL - 11
JO - Antibiotics
JF - Antibiotics
IS - 2
M1 - 252
ER -